Prevention of Schizophrenia Relapse with Extended Release Quetiapine Fumarate Dosed Once Daily: A Randomized, Placebo-Controlled Trial in Clinically Stable Patients

| November 8, 2007 | 0 Comments

by Joseph Peuskens, Jitendra Trivedi, Sergiy Malyarov, Martin Brecher, Ola Svensson, Frank Miller, Inger Persson, and Didier Meulien on behalf of the Study D1444C00004 investigators

Dr. Peuskens is with Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Belgium; Dr. Trivedi is with King George Medical University, Lucknow, India; Dr. Malyarov is with Kyiv Psychoneurological Hospital, Kyiv, Ukraine; Dr. Brecher is with AstraZeneca Pharmaceuticals, Wilmington, Delaware, US; and Drs. Svensson, Miller, Persson, and Meulien are with AstraZeneca Research and Development in Södertälje, Sweden.


The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , ,

Category: Original Research, Past Articles, Psychiatry, Schizophrenia

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.